Portal de Periódicos da CAPES

Society of cardiac angiography and interventions: Suggested management of the no‐reflow phenomenon in the cardiac catheterization laboratory

2003; Wiley; Volume: 60; Issue: 2 Linguagem: Inglês

10.1002/ccd.10620

1522-726X

Lloyd W. Klein, Morton J. Kern, Peter B. Berger, Timothy A. Sanborn, Peter C. Block, Joseph D. Babb, Carl L. Tommaso, John McB. Hodgson, Ted Feldman,

Coronary Interventions and Diagnostics

Catheterization and Cardiovascular InterventionsVolume 60, Issue 2 p. 194-201 Coronary Artery Disease Society of cardiac angiography and interventions: Suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory Lloyd W. Klein MD, Corresponding Author Lloyd W. Klein MD [email protected] Rush-Presbyterian-St. Luke's Medical Center, Chicago, IllinoisRush-Presbyterian-St. Luke's Medical Center, Jelke Pavilion, Suite 1035, 1653 W. Congress Parkway, Chicago, IL 60612Search for more papers by this authorMorton J. Kern MD, Morton J. Kern MD St. Louis University, St. Louis, MissouriSearch for more papers by this authorPeter Berger MD, Peter Berger MD Mayo Clinic, Rochester, MissouriSearch for more papers by this authorTimothy Sanborn MD, Timothy Sanborn MD Evanston Northwestern Healthcare, Evanston, IllinoisSearch for more papers by this authorPeter Block MD, Peter Block MD Emory University, Atlanta, GeorgiaSearch for more papers by this authorJoseph Babb MD, Joseph Babb MD East Carolina University, Brody School of Medicine, Greenville, North CarolinaSearch for more papers by this authorCarl Tommaso MD, Carl Tommaso MD Rush North Shore Medical Center, Skokie, IllinoisSearch for more papers by this authorJohn McB. Hodgson MD, John McB. Hodgson MD MetroHealth Medical Center, Cleveland, OhioSearch for more papers by this authorTed Feldman MD, Ted Feldman MD Evanston Northwestern Healthcare, Evanston, IllinoisSearch for more papers by this author Lloyd W. Klein MD, Corresponding Author Lloyd W. Klein MD [email protected] Rush-Presbyterian-St. Luke's Medical Center, Chicago, IllinoisRush-Presbyterian-St. Luke's Medical Center, Jelke Pavilion, Suite 1035, 1653 W. Congress Parkway, Chicago, IL 60612Search for more papers by this authorMorton J. Kern MD, Morton J. Kern MD St. Louis University, St. Louis, MissouriSearch for more papers by this authorPeter Berger MD, Peter Berger MD Mayo Clinic, Rochester, MissouriSearch for more papers by this authorTimothy Sanborn MD, Timothy Sanborn MD Evanston Northwestern Healthcare, Evanston, IllinoisSearch for more papers by this authorPeter Block MD, Peter Block MD Emory University, Atlanta, GeorgiaSearch for more papers by this authorJoseph Babb MD, Joseph Babb MD East Carolina University, Brody School of Medicine, Greenville, North CarolinaSearch for more papers by this authorCarl Tommaso MD, Carl Tommaso MD Rush North Shore Medical Center, Skokie, IllinoisSearch for more papers by this authorJohn McB. Hodgson MD, John McB. Hodgson MD MetroHealth Medical Center, Cleveland, OhioSearch for more papers by this authorTed Feldman MD, Ted Feldman MD Evanston Northwestern Healthcare, Evanston, IllinoisSearch for more papers by this author First published: 23 September 2003 https://doi.org/10.1002/ccd.10620Citations: 48Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of no-reflow after percutaneous coronary intervention. Circulation 1994; 89: 2514– 2518. 2 Abbo KM, Dooris M, Glazier S, et al. No-reflow after percutaneous coronary intervention: clinical and angiographic characteristics, treatment and outcome. Am J Cardiol 1995; 75: 778– 782. 3 Feld H, Lichstein E, Schachter J, Shani J. Early and late angiographic findings of the "no-reflow" phenomenon following direct angioplasty as primary treatment for acute myocardial infarction. Am Heart J 1992; 123: 782– 784. 4 Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974; 54: 1496– 1508. 5 Kloner RA. No-reflow revisited. J Am Coll Cardiol 1989; 14: 1814– 1815. 6 Kitazume H, Iwama T, Kubo H, et al. No-reflow phenomenon during percutaneous transluminal coronary angioplasty. Am Heart J 1988; 116: 211– 215. 7 Wilson RF, Lesser JR, Laxson DD, et al. Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesions. Lancet 1989; 1(8642): 801– 811. 8 Feld H, Schulhoff N, Lichstein E, et al. Direct angioplasty as primary treatment for acute myocardial infarction results in the no-reflow phenomenon predicts a high mortality rate. Circulation 1992; 86: I135. 9 Safian RD, Niazi KA, Strzelecki M, et al. Detailed angiographic analysis of high-speed mechanical rotational atherectomy in human coronary arteries. Circulation 1993; 88: 961– 968. 10 Ellis SG, Popma JJ, Buchbinder M, et al. Relation of clinical presentation, stenosis morphology, and operator technique to the procedural results of rotational atherectomy and rotational atherectomy-facilitated angioplasty. Circulation 1994; 89: 882– 892. 11 Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J 2001; 22: 729– 739. 12 Bates ER, Krell MJ, Dean EN, O'Neill WW, Vogel RA. Demonstration of the "no-reflow" phenomenon by digital coronary arteriography. Am J Cardiol 1986; 57: 177– 178. 13 Schafer S, Montz R, Mathey D. Scintigraphic evidence of the no-reflow phenomenon in human beings after coronary thrombolysis. J Am Coll Cardiol 1985; 5: 593– 598. 14 Kloner RA. Does reperfusion exist in humans? J Am Coll Cardiol 1993; 21: 337– 345. 15 Webb JG, Curere RG, Virmani R, et al. Retrieval and analysis of particulate debris after saphenous vein graft intervention. J Am Coll Cardiol 1999; 34: 465– 475. 16 Sanborn TA, Faxon DP, Waugh D, et al. Transluminal angioplasty in experimental atherosclerosis: analysis for embolization using an in vivo perfusion system. Circulation 1982; 66: 917– 922. 17 Hori M, Inoue M, Kitakaze M, et al. Role of adenosine in hyperemic response of coronary blood flow in microembolization. Am J Physiol 1986;– 250(3 Pt 2): H509– H518. 18 Leosco D, Fineschi M, Pierli C, et al. Intracoronary serotonin release after high-pressure coronary stenting. Am J Cardiol 1999; 84: 1317– 1322. 19 Mallieni A, Schwartz PJ, Zanchetti A. A sympathetic reflex elicited by experimental coronary occlusion. Am J Physiol 1969; 217: 703– 709. 20 Gregorini L, Marco J, Kozakova R, et al. Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation 1999; 59: 482– 490. 21 Lefroy DC, Wharton J, Crake T. Regional changes in angiotensin II receptor density after experiencing myocardial infarction. J Mol Cell Cardiol 1996; 28: 429– 440. 22 Lyons D, Webster J, Benjamin N. Angiotensin II adrenergic sympathetic constrictor action in humans. Circulation 1995; 91: 1457– 1460. 23 Lincoff AM, Topol EJ. Illusion of reperfusion: does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 1993; 88: 1361– 1374. 24 Hearse DJ, Rolli R. Reperfusion induced injury: manifestations, mechanisms, and clinical relevance. Cardiovasc Res 1992; 26: 101– 108. 25 Asunuma T, Tanabe K, Ochiai K, et al. Relation between progressive microvascular damage and intramyocardial hemorrhage in patients with reperfused anterior myocardial infarction: myocardial contrast echocardiographic study. Circulation 1997; 96: 448– 453. 26 Iliceto S, Galiuto L, Marchese A, et al. Functional role of microvascular integrity in patients with infarct-related artery patency after acute myocardial infarction. Eur Heart J 1997; 18: 618– 624. 27 Jeremy RW, Links JM, Becker CC. Progressive failure of coronary flow during reperfusion of myocardial infarction: documentation of the no-reflow phenomenon with positron emission tomography. J Am Coll Cardiol 1990; 16: 695– 704. 28 Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998; 97: 765– 772. 29 Rochitte CE, Lima JAC, Bluemke DA, et al. Magnitude and time course of microvascular obstruction and tissue injury after myocardial infarction. Circulation 1998; 98: 1006– 1014. 30 Silva JA, White CJ, Ramee SR, et al. Treatment of coronary stent thrombosis with rheolytic thrombectomy: Results from a multicenter experience. Cathet Cardiovasc Intervent 2003; 58: 11– 17. 31 Safian RD. No-reflow. In: RD Safian, M Freed, editors. The manual of interventional cardiology, 3rd ed. Royal Oak, MI: Physicians Press; 2001. p 413– 421. 32 Kaplan BM, Benzuly KH, Kinn JW, et al. Treatment of no-reflow in degenerated saphenous vein graft intervention: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn 1997; 39: 113– 118. 33 Roffi M, Mukherjee D, Chew DP, et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation 2002; 106: 3063– 3067. 34 Ellis SG, Lincoff MA, Miller D, et al. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. J Am Coll Cardiol 1998; 32: 1619– 1623. 35 Sdringola S, Assali AR, Ghani M, et al. Risk assessment of slow or no-reflow phenomenon in aortocoronary vein graft percutaneous intervention. Cathet Cardiovasc Intervent 2001; 54: 318– 324. 36 Sdringola S, Assali A, Ghani M, et al. Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no-reflow phenomenon. Cathet Cardiovasc Intervent 2000; 51; 394– 399. 37 Baim DS, Wahr D, George B, et al., Saphenous Vein Graft Angioplasty Free of Emboli Randomized (SAFER) trial investigators. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002; 105: 1285– 1290. 38 Shaknovich A, Forman ST, Parikh MA, et al. Novel distal occluder washout method for the prevention of no-reflow during stenting of saphenous vein grafts. Cathet Cardiovasc Intervent 1999; 47: 397– 403. 39 Carlino M, De Gregorio J, Di Mario C, et al. Prevention of distal embolization during saphenous vein graft lesion angioplasty: experience with a new temporary occlusion and aspiration system. Circulation 1999; 99: 3221– 3223. 40 Savage MP, Ramee SR, Ho KKL, et al. Rheolytic thrombectomy for the treatment of aortocoronary venous bypass graft thrombosis: results of the VEGAS II trial. Circulation 1999; 100(Suppl 1): 435. 41 Braden GA, Xenopolous NP, Young T, et al. Transluminal extraction catheter atherectomy followed by immediate stenting in treatment of saphenous vein grafts. J Am Coll Cardiol 1997; 30: 657– 663. 42 Rosenschein U, Gaul G, Erbel R. Percutaneous transluminal therapy of occluded saphenous vein grafts: can the challenge be met with ultrasound thrombolysis. Circulation 1999; 99: 26– 29. 43 Moses JW, Whitlow PL, Kuntz RE, et al. Myocardial infarction after rotational atherectomy: predictors and influence on late outcome in the STRATAS trial. J Am Coll Cardiol 1998; 31: 455A. 44 Williams MS, Coller BS, Vaananen HJ, et al. Activation of platelets in platelet-rich plasma by rotablation is speed-dependent and can be inhibited by abciximab. Circulation 1998; 98: 742– 748. 45 Hanna GP, Yhiop P, Fujise K, et al. Intracoronary adenosine administered during rotational atherectomy of complex lesions in native coronary arteries reduces the incidence of no-reflow phenomenon. Cathet Cardiovasc Intervent 1999; 48: 275– 278. 46 Cohen BM, Weber VJ, Blum RR, et al. Cocktail attenuation of rotational ablation flow effects (CARAFE) pilot study. Cathet Cardiovasc Diagn 1996; 39 (Suppl 3): 69– 72. 47 Baim DS, Carrozza JP. Understanding the no-reflow problem. Cathet Cardiovasc Diagn 1996; 39: 7– 8. 48 O'Murchu B, Foreman RD, Shaw RE, et al. Role of intraaortic balloon pump counterpulsation in high risk coronary rotational atherectomy. J Am Coll Cardiol 1995; 26: 1270– 1275. 49 Pomerantz RM, Kuntz RE, Diver DJ, et al. Intracoronary verapamil for the treatment of distal microvascular coronary artery spasm following percutaneous transluminal coronary angioplasty. Cathet Cardiovasc Diagn 1991; 24: 283– 285. 50 Taniyama Y, Ito H, Iwakura K, et al. Beneficial effects of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 30: 1193– 1199. 51 Fischell TA, Carter AJ, Foster MT et al. Reversal of "no-reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn 1998; 45: 366– 367. 52 Assali AR, Sdringola S, Ghani M, et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no-reflow" phenomenon. Cathet Cardiovasc Intervent 2000; 51: 27– 31. 53 Hillegass WB, Dean NA, Liao L, et al. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions. J Am Coll Cardiol 2001; 37: 1335– 1343. 54 Rawitscher D, Levin TN, Cohen I, et al. Rapid reversal of no-reflow using abciximab after coronary device intervention. Cathet Cardiovasc Diagn 1997; 42: 187– 190. 55 Weyrens FJ, Mooney J, Lesser J, et al. Intracoronary diltiazem for microvascular spasm after interventional therapy. Am J Cardiol 1995; 75: 849– 850. 56 Jalinous F, Mooney JA, Mooney MR. Pretreatment with intracoronary diltiazem reduces non-Q wave myocardial infarction following directional atherectomy. J Invas Cardiol 1997; 9: 270– 273. 57 Ito H, Taniyama Y, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 30: 1193– 1199. 58 Ishihara M, Sato H, Tateishi H, et al. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J 1996; 132: 959– 963. 59 Skelding KA, Goldstein JA, Mehta L, et al. Resolution of refractory no-reflow with intracoronary epinephrine. Cathet Cardiovasc Intervent 2002; 57: 305– 309. 60 Fugit MD, Rubal BT, Donovan DJ. Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow. J Invas Cardiol 2000; 12: 80– 85. 61 Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999; 33: 654– 660. 62 Port SC, Patel S, Schmidt DH. Effects of intracoronary balloon counterpulsation on myocardial blood flow in patients with severe coronary artery disease. J Am Coll Cardiol 1984; 3: 1367– 1374. 63 Kern MJ, Aguirre F, Bach R, et al. Augmentation of coronary blood flow by intra-aortic balloon pumping in patients after coronary angioplasty. Circulation 1993; 87: 500– 511. 64 Kloner RA, Alker KJ. The effect of streptokinase on intramyocardial hemorrhage, infarct size, and the "no-reflow" phenomenon during coronary reperfusion. Circulation 1984; 70: 513– 521. 65 Yaryura RA, Zaqqa M, Ferguson JJ. Complications associated with combined use of abciximab and an intracoronary thrombolytic agent (urokinase or tissue-type plasminogen activator). Am J Cardiol 1998; 82: 518– 519. Citing Literature Volume60, Issue2October 2003Pages 194-201 SCAI Member Sign in ReferencesRelatedInformation